Gul, A., Leyland-Jones, B., Dey, N., & De, P. (2018). A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: A genomic algorithm-based treatment approach. Am J Cancer Res.
Citação norma ChicagoGul, Anita, Brain Leyland-Jones, Nandini Dey, and Pradip De. "A Combination of the PI3K Pathway Inhibitor Plus Cell Cycle Pathway Inhibitor to Combat Endocrine Resistance in Hormone Receptor-positive Breast Cancer: A Genomic Algorithm-based Treatment Approach." Am J Cancer Res 2018.
MLA citiranjeGul, Anita, Brain Leyland-Jones, Nandini Dey, and Pradip De. "A Combination of the PI3K Pathway Inhibitor Plus Cell Cycle Pathway Inhibitor to Combat Endocrine Resistance in Hormone Receptor-positive Breast Cancer: A Genomic Algorithm-based Treatment Approach." Am J Cancer Res 2018.